Medtronic Receives FDA Approval For Endeavor(R) Zotarolimus-Eluting Coronary Stent System

Marking a major development in the field of interventional cardiology, Medtronic, Inc. (NYSE: MDT), announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the Endeavor(R) Zotarolimus-Eluting Coronary Stent System to be used in the treatment of coronary artery disease, which affects an estimated 13 million people in the United States and is the country’s leading cause of death.

More: continued here

Filed under: Cardiovascular on February 7th, 2008